|
AMGN
|
Amgen Inc.
|
12.55%
|
US
|
NASDAQ
|
|
GILD
|
Gilead Sciences, Inc.
|
8.83%
|
US
|
NASDAQ
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
6.78%
|
US
|
NASDAQ
|
|
MRNA
|
Moderna, Inc.
|
5.77%
|
US
|
NASDAQ
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
5.26%
|
US
|
NASDAQ
|
|
IQV
|
IQVIA Holdings, Inc.
|
5.00%
|
US
|
NYSE
|
|
BIIB
|
Biogen Idec Inc.
|
4.83%
|
US
|
NASDAQ
|
|
BGNE
|
BeiGene, Ltd.
|
4.52%
|
US
|
NASDAQ
|
|
ILMN
|
Illumina, Inc.
|
4.40%
|
US
|
NASDAQ
|
|
BNTX
|
BioNTech SE
|
4.20%
|
US
|
NASDAQ
|
|
BMRN
|
BioMarin Pharmaceutical Inc.
|
4.08%
|
US
|
NASDAQ
|
|
ALNY
|
Alnylam Pharmaceuticals, Inc.
|
4.07%
|
US
|
NASDAQ
|
|
ICLR
|
ICON plc
|
3.91%
|
US
|
NASDAQ
|
|
SGEN
|
Seattle Genetics, Inc.
|
3.87%
|
US
|
NASDAQ
|
|
ARGX
|
argenx SE
|
3.69%
|
US
|
NASDAQ
|
|
INCY
|
Incyte Corporation
|
3.14%
|
US
|
NASDAQ
|
|
TECH
|
Techne Corporation
|
3.09%
|
US
|
NASDAQ
|
|
QGEN
|
Qiagen N.V.
|
2.72%
|
US
|
NYSE
|
|
CRL
|
Charles River Laboratories International, Inc.
|
2.67%
|
US
|
NYSE
|
|
RGEN
|
Repligen Corporation
|
1.86%
|
US
|
NASDAQ
|